Glaukos Corporation (FRA:6GJ)

Germany flag Germany · Delayed Price · Currency is EUR
92.50
+1.50 (1.65%)
At close: Dec 5, 2025
-28.29%
Market Cap 5.35B
Revenue (ttm) 400.43M
Net Income (ttm) -74.67M
Shares Out n/a
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 92.50
Previous Close 91.00
Day's Range 92.50 - 92.50
52-Week Range 63.50 - 152.00
Beta n/a
RSI 69.97
Earnings Date Feb 26, 2026

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 1998
Employees 995
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6GJ
Full Company Profile

Financial Performance

In 2024, Glaukos's revenue was $383.48 million, an increase of 21.85% compared to the previous year's $314.71 million. Losses were -$146.37 million, 8.70% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.